Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA · Pharmaceuticals
Snapshot
Unlock Sun Pharmaceutical Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations alongside active pharmaceutical ingredients. The company operates across numerous therapeutic segments, including cardiology, oncology, dermatology, and neuro-psychiatry, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of complex generic medications, speciality formulations, and active pharmaceutical ingredients. Its business model leverages a broad manufacturing footprint to supply healthcare providers and consumers with affordable medicines across various therapeutic categories.
Growth Outlook
Growth is driven by the expansion of the company's speciality portfolio and the continued penetration of generic markets globally. The firm focuses on high-barrier therapeutic areas to maintain competitive advantage and long-term value creation.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance at manufacturing facilities can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector exerts significant downward pressure on profit margins across key markets.
- Litigation Risk. As a major pharmaceutical player, the company is susceptible to intellectual property disputes and product liability litigation.
- Currency Volatility. Significant international operations expose the company to fluctuations in foreign exchange rates, which can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharmaceutical Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹61,631 Cr
TTM · consolidated
NET PROFIT
₹10,987 Cr
TTM · consolidated
EPS
₹45.70
TTM · consolidated
RETURN ON EQUITY
13.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.9%
TTM · consolidated
P/E
38.7×
Q2 FY27 · consolidated
EV/EBITDA
20.1x
Q2 FY27 · consolidated
EBITDA MARGIN
33.0%
TTM · consolidated
NET PROFIT MARGIN
12.3%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.25L Cr | 38.7× | 20.10 | 12.1% | 33.0% | 13.2% | 17.9% | +4.7% |
Divi's Laboratories Ltd.DIVISLAB | ₹2.64L Cr | 90.2× | 59.72 | 16.3% | 39.3% | 18.4% | 23.1% | +47.6% |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.75L Cr | 77.6× | 32.81 | 42.1% | 32.9% | 15.7% | 15.5% | +29.1% |
Laurus Labs Ltd.LAURUSLABS | ₹1.27L Cr | 94.6× | 53.43 | 23.0% | 30.9% | 24.5% | 27.9% | +146.2% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.24L Cr | 27.6× | 15.34 | 21.1% | 30.7% | 18.0% | 20.1% | +27.3% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 38.7× | 20.10 | -0.7% | 19.6% | 8.4% | 11.1% | -7.6% |
As of Q2 FY27
Financials
Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA · Pharmaceuticals
Snapshot
Unlock Sun Pharmaceutical Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations alongside active pharmaceutical ingredients. The company operates across numerous therapeutic segments, including cardiology, oncology, dermatology, and neuro-psychiatry, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of complex generic medications, speciality formulations, and active pharmaceutical ingredients. Its business model leverages a broad manufacturing footprint to supply healthcare providers and consumers with affordable medicines across various therapeutic categories.
Growth Outlook
Growth is driven by the expansion of the company's speciality portfolio and the continued penetration of generic markets globally. The firm focuses on high-barrier therapeutic areas to maintain competitive advantage and long-term value creation.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance at manufacturing facilities can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector exerts significant downward pressure on profit margins across key markets.
- Litigation Risk. As a major pharmaceutical player, the company is susceptible to intellectual property disputes and product liability litigation.
- Currency Volatility. Significant international operations expose the company to fluctuations in foreign exchange rates, which can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharmaceutical Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹61,631 Cr
TTM · consolidated
NET PROFIT
₹10,987 Cr
TTM · consolidated
EPS
₹45.70
TTM · consolidated
RETURN ON EQUITY
13.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.9%
TTM · consolidated
P/E
38.7x
Q2 FY27 · consolidated
EV/EBITDA
20.1x
Q2 FY27 · consolidated
EBITDA MARGIN
33.0%
TTM · consolidated
NET PROFIT MARGIN
12.3%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27